fashion -WSS

fashion

author：focus 2025-09-05 05:55:26 - browse：21719

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Patients, digital health players weigh in on FTC's data privacy plan

focus

WSS

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

Idaho college killings prosecutors challenge defense's grand jury claims

Timeline: How the deadly wildfires took over Maui day by day

BMS, looking to build heart drug business, turns to AI for diagnosis

Megan Rapinoe shares emotional post following US Women's World Cup exit

explore

fashion

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Megan Rapinoe shares emotional post following US Women's World Cup exit

Virginia high school admissions case could be legal follow

International team creates first chimeric human

Apple is now the first public company to be valued at $3 trillion

Health AI: on the border between health care and tech

In Memoriam: Notable people who died in 2023

ALS groups 'won't be played again' by the FDA, drug sponsors

United colonoscopy coverage change 'may cost lives,' doctors say

An inside look at PIPEs, biotech's buzzy new financing tool

knowledge

Clinical trials giant ICON acquires HumanFirst

Novo Nordisk touts Wegovy study, but still struggling with supply

Judge sides with young activists in first

Kenai launches with $82 million for Parkinson’s stem cell therapy

Idaho college killings prosecutors challenge defense's grand jury claims

Patients, digital health players weigh in on FTC's data privacy plan

focus

focus

focus

hotspot